Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252753 · ClinicalTrials.gov registry record
Observational Study Protocol: LIVER-R
A clinical trial of Hepatobiliary Cancers, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 4,490
- Enrollment target
- 20
- Study locations
NCT06252753 is a study of Hepatobiliary Cancers that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,490 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06252753, a study of Hepatobiliary Cancers, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 4,490 participants
- Enrollment target
- 20
- Study locations
Study Summary
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence).
Conditions Studied
Interventions
- OTHER Durvalumab-based combination therapies in observational study setting
Study Locations (20)
California
- Research Site - Coronado
- Research Site - Los Angeles
- Research Site - Walnut Creek
Florida
- Research Site - Clermont
- Research Site - Gainesville
- Research Site - Tampa
Alabama
- Research Site - Birmingham
- Research Site - Mobile
Illinois
- Research Site - Evergreen Park
- Research Site - Hinsdale
Pennsylvania
- Research Site - Bethlehem
- Research Site - Philadelphia
Texas
- Research Site - Dallas
- Research Site - Temple
Arizona
- Research Site - Phoenix
Georgia
- Research Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,490 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2030-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06252753
The ClinicalTrials.gov registry entry for NCT06252753 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatobiliary Cancers appearing as the primary indexed condition, and to 1 intervention - of which Durvalumab-based combination therapies in observational study setting is the first listed.
NCT06252753 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06252753 about?
NCT06252753 is a clinical study titled "Observational Study Protocol: LIVER-R". Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diag...
What is the current status of trial NCT06252753?
This trial is currently recruiting. The enrollment target is 4,490 participants. The study started on 2023-03-16. Estimated completion is 2030-12-30.
What conditions does trial NCT06252753 study?
This clinical trial studies the following conditions: Hepatobiliary Cancers.
What interventions are being tested in trial NCT06252753?
The interventions under investigation include: Durvalumab-based combination therapies in observational study setting (OTHER).
Who is sponsoring clinical trial NCT06252753?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252753 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.